Spectranetics

Spectranetics is a medical technology company focused on vascular intervention and lead management solutions. Founded in 1984, it became part of Royal Philips' Image-Guided Therapy business group after its acquisition in 2017. The company is known for pioneering excimer laser technology to treat coronary and peripheral arterial disease, receiving FDA approval for these applications in 1993. The core offerings of Spectranetics include advanced lead management devices and extraction sheaths for the precise removal of cardiac implantable electronic device (CIED) leads, especially in infection cases. They also provide a comprehensive vascular care portfolio that supports various procedures involving peripheral, aortic, visceral, arterial, and venous vessels. Their solutions for coronary artery disease aim to enhance catheterization lab performance and improve patient outcomes, integrating seamlessly with Philips’ broader coronary suite. Spectranetics serves a global customer base, including hospitals, cardiovascular specialists, and interventional cardiology labs. With over 900 employees, the company has demonstrated strong growth, reflecting its commitment to innovative tools for managing complex vascular and cardiac device challenges.

• Employees 270
• Founded 1984
• Annual Revenue $270823000
• Total Funding $143750000